Routine Monitoring Visits (RMVs) are essential for maintaining the quality and compliance of clinical trials. Two core activities performed during these visits are Source Data Verification (SDV) and Source Data Review (SDR). While often used interchangeably, these terms have distinct meanings and roles in ensuring data integrity. This tutorial explains their differences, execution strategies, and best practices during routine visits.

What Is Source Data Verification (SDV)?

SDV refers to the process of checking that the data recorded in Case Report Forms (CRFs) or Electronic Data Capture (EDC) systems accurately reflect the original source documents. CRAs (Clinical Research Associates) perform SDV to confirm that trial data is:

• Accurate and consistent with source records (e.g., patient charts, lab reports)
• Complete, timely, and legible
• Documented in accordance with GCP and protocol requirements

What Is Source Data Review (SDR)?

SDR involves the qualitative assessment of source data to ensure protocol compliance and adherence to GCP. Unlike SDV, which focuses on data point accuracy, SDR emphasizes the quality, logic, and clinical relevance of the data. CRAs use SDR to identify trends such as:

• Improper documentation
• Missing visit procedures or lab tests
• Deviation from inclusion/exclusion criteria

As per EMA and Stability Studies insights, both SDV and SDR are expected to be performed based on a risk-based monitoring strategy tailored to the trial phase and protocol design.

Key Differences Between SDV and SDR

Steps to Perform SDV During RMVs

1. Access the EDC and list subjects requiring SDV
2. Open source documents (electronic or paper)
3. Match each data point in the CRF with source entries
4. Mark verified fields in the EDC with audit trail
5. Flag any discrepancies or missing data
6. Generate queries for unresolved issues

Steps to Perform SDR During RMVs

1. Review medical history, inclusion/exclusion criteria compliance
2. Assess AE/SAE documentation for completeness
3. Evaluate the sequence and completeness of visit procedures
4. Check informed consent process documentation
5. Identify gaps in documentation or potential deviations
6. Provide feedback to the site on findings

Best Practices for CRAs

• Prioritize SDV/SDR based on enrollment and data complexity
• Use EDC dashboards to track SDV progress
• Apply 100% SDV for critical data points (e.g., informed consent, primary endpoints)
• Document all findings in the Monitoring Visit Report (MVR)
• Align SDV/SDR practices with sponsor’s monitoring SOPs from Pharma SOPs

Risk-Based Monitoring and SDV/SDR

Risk-Based Monitoring (RBM) integrates centralized monitoring with adaptive SDV and SDR. Instead of applying 100% SDV uniformly, it allows for focused verification of critical data points based on risk assessment. This enhances efficiency while maintaining data quality and regulatory compliance.

Examples of critical data for 100% SDV:

• Informed consent dates
• Primary endpoint measurements
• Serious Adverse Events (SAEs)
• Investigational Product (IP) dispensing and dosing

Tools That Support SDV and SDR

• EDC systems like Medidata Rave, Oracle InForm
• Electronic Source (eSource) solutions
• Monitoring logs in CTMS (e.g., Veeva Vault CTMS)
• Audit trail tracking tools

Regulatory Expectations

According to ICH E6(R2) and USFDA guidance, SDV and SDR are essential to verifying the validity of trial data. While remote monitoring can supplement on-site efforts, proper documentation and justification are critical when reducing SDV intensity.

Common Pitfalls in SDV/SDR

• Missing source documents for reviewed CRF entries
• Over-reliance on paper notes when EHR data is available
• Incorrect version of Informed Consent Form (ICF) used
• Unreported discrepancies due to lack of documentation

Conclusion

SDV and SDR are complementary processes that ensure the integrity and compliance of clinical trial data. CRAs play a pivotal role in applying both effectively during routine monitoring visits. By understanding their scope, applying best practices, and using robust tools, sponsors and site teams can ensure successful audits, inspections, and ultimately, high-quality clinical outcomes.